| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO
1 company
Jay R. Luly is President and CEO at ENTA. From January 2015 to February 2026, the filings on record show 1 open-market purchase and 11 sales. Jay R. Luly's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $9.0M at current prices.
Historically, Jay R. Luly's trades have earned a strong insider score of 71/100 across 7 rated trades. Over a 12-month horizon, 83.3% of those trades were profitable, with an average 12-month return of +29.3%.
The ENTA filings lean toward selling, a net 139,543 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 20, 2015 | ENTA Enanta Pharmaceuticals Inc | President and CEO | Sell | 15,000 | $35.35 | $530,289.00 | -3.0% | |
| Jan 5, 2015 | ENTA Enanta Pharmaceuticals Inc | President and CEO | Sell | 15,000 | $50.43 | $756,462.50 | -2.9% |